Cwm LLC Has $21.90 Million Stake in The Cigna Group (NYSE:CI)

Cwm LLC decreased its position in The Cigna Group (NYSE:CI) by 11.2% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 73,142 shares of the health services provider’s stock after selling 9,241 shares during the period. Cwm LLC’s holdings in The Cigna Group were worth $21,902,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Axiom Financial Strategies LLC acquired a new position in shares of The Cigna Group during the first quarter valued at about $212,000. Fairfield Bush & CO. bought a new stake in shares of The Cigna Group during the first quarter worth about $40,000. Cibc World Market Inc. increased its position in shares of The Cigna Group by 52.6% during the first quarter. Cibc World Market Inc. now owns 18,975 shares of the health services provider’s stock worth $4,547,000 after acquiring an additional 6,538 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of The Cigna Group by 6.5% during the first quarter. Vontobel Holding Ltd. now owns 9,212 shares of the health services provider’s stock worth $2,265,000 after acquiring an additional 566 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in The Cigna Group by 36.5% in the 1st quarter. Sequoia Financial Advisors LLC now owns 1,283 shares of the health services provider’s stock worth $307,000 after purchasing an additional 343 shares in the last quarter. Institutional investors and hedge funds own 86.99% of the company’s stock.

Analyst Ratings Changes

CI has been the topic of a number of research analyst reports. Sanford C. Bernstein upgraded shares of The Cigna Group from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $330.00 to $372.00 in a research note on Thursday, January 4th. Wells Fargo & Company boosted their target price on shares of The Cigna Group from $334.00 to $348.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $384.00 price target on shares of The Cigna Group in a research note on Wednesday, April 10th. Barclays began coverage on shares of The Cigna Group in a research note on Wednesday, March 6th. They set an “overweight” rating and a $393.00 price target on the stock. Finally, StockNews.com upgraded shares of The Cigna Group from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 14th. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $362.14.

Insider Activity at The Cigna Group

In related news, CEO David Cordani sold 31,209 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $355.17, for a total transaction of $11,084,500.53. Following the transaction, the chief executive officer now owns 348,054 shares of the company’s stock, valued at approximately $123,618,339.18. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other The Cigna Group news, CEO David Cordani sold 31,209 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $355.17, for a total value of $11,084,500.53. Following the sale, the chief executive officer now owns 348,054 shares of the company’s stock, valued at approximately $123,618,339.18. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Hoeltzel Mary T. Agoglia sold 4,867 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $330.48, for a total transaction of $1,608,446.16. Following the completion of the sale, the senior vice president now directly owns 2,102 shares in the company, valued at approximately $694,668.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 114,144 shares of company stock valued at $39,296,330. Insiders own 0.70% of the company’s stock.

The Cigna Group Price Performance

Shares of NYSE:CI opened at $352.39 on Monday. The company’s fifty day moving average price is $348.41 and its 200-day moving average price is $315.91. The firm has a market capitalization of $103.02 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 1.08 and a beta of 0.56. The Cigna Group has a one year low of $240.50 and a one year high of $365.71. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.67 and a quick ratio of 0.67.

The Cigna Group (NYSE:CI) last released its earnings results on Friday, February 2nd. The health services provider reported $6.79 EPS for the quarter, beating the consensus estimate of $6.54 by $0.25. The Cigna Group had a net margin of 2.64% and a return on equity of 13.59%. The company had revenue of $51.15 billion for the quarter, compared to analyst estimates of $48.91 billion. During the same quarter last year, the firm earned $4.96 EPS. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. On average, equities research analysts anticipate that The Cigna Group will post 28.36 earnings per share for the current fiscal year.

The Cigna Group Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 21st. Investors of record on Wednesday, March 6th were issued a dividend of $1.40 per share. The ex-dividend date of this dividend was Tuesday, March 5th. This represents a $5.60 annualized dividend and a dividend yield of 1.59%. This is a positive change from The Cigna Group’s previous quarterly dividend of $1.23. The Cigna Group’s dividend payout ratio (DPR) is currently 32.20%.

About The Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.